Korsana Biosciences’ preclinical Alzheimer’s disease drug comes from a platform technology that enables antibodies to cross the blood-brain barrier. Roche and AbbVie have clinical-stage drugs taking a similar approach to Alzheimer’s.Alzheimer’s disease can be treated with antibodies that clear away plaques of amyloid protein, but these medicines require frequent dosing and they introduce serious safety […]
